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Abstract
Background: In Sri Lanka, varicella zoster virus (VZV) is typically acquired during adulthood with significant associated
disease morbidity and mortality. T cells are believed to be important in the control of VZV replication and in the prevention
of reactivation. The relationship between viral load, disease severity and cellular immune responses in primary VZV infection
has not been well studied.
Methodology: We used IFNc ELISpot assays and MHC class II tetramers based on VZV gE and IE63 epitopes, together with
quantitative real time PCR assays to compare the frequency and phenotype of specific T cells with virological and clinical
outcomes in 34 adult Sri Lankan individuals with primary VZV infection.
Principal Findings: Viral loads were found to be significantly higher in patients with moderate to severe infection compared
to those with mild infection (p,0.001) and were significantly higher in those over 25 years of age (P,0.01). A significant
inverse correlation was seen between the viral loads and the ex vivo IFNc ELISpot responses of patients (P,0.001, r=20.85).
VZV-specific CD4+ T cells expressed markers of intermediate differentiation and activation.
Conclusions: Overall, these data show that increased clinical severity in Sri Lankan adults with primary VZV infection
associates with higher viral load and reduced viral specific T cell responses.
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Introduction
Primary infection with varicella zoster virus (VZV) results in
chickenpox, which is usually a benign self-limiting illness,
characterized by fever and a generalized pruritic vesicular rash.
However, in certain groups of individuals such as neonates, adults,
pregnant women and immunosuppressed individuals, it may cause
severe disease and can sometimes be fatal. Adults are 9 to 15 times
more likely to be hospitalized [1] and 25 times more likely than
children to die from varicella [2]. Varicella associated complica-
tions such as pneumonia are more common among adults than
children [3]. Primary varicella in immunosuppressed individuals
may result in visceral dissemination, multi organ failure and death
[4–6].
Although varicella infections occur worldwide, there are marked
differences in its epidemiology in tropical and temperate climates.
In temperate climates, chickenpox is a common childhood illness
and seropositivity rates range from 53% to 100% in 5 year olds,
and in 20–30 years olds it is typically greater than 80% [7–9]. In
contrast, in the tropics, due to the lower incidence of VZV
infection among children, it more commonly affects adults [10–
12], thus resulting in significant morbidity and mortality. In Sri
Lanka 56.2% of females of child bearing age were antibody
negative for VZV [13]. Approximately 1000 patients with VZV
infections are admitted to just one infectious diseases hospital in
Colombo in Sri Lanka each year [14] and many patients develop
complications with an overall mortality rate of 4.2% [14]. VZV is
therefore a significant health problem in Sri Lanka and
understanding of the immunological correlates of disease will be
important for new vaccine and treatment developments.
VZV infects many cell types in the host during acute infection,
including T cells, B cells, monocytes and dendritic cells [15–17].
Infection of T cells by the virus is thought to be one of the main
mechanisms by which the virus disseminates, subsequently
infecting keratinocytes and other cells [17,18]. During the
viraemic phase, which is thought to be highly cell associated
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3789[19], VZV is believed to predominantly infect T cells [20,21]. In
acute primary VZV infection, viral loads in children have been
reported in the range of 1 to 5000 viral copies per 10
5 PBMCs
[22,23] and 100 to 10000 per ml of blood [24]. In many infectious
diseases, the degree of viraemia is thought to be associated with
severity of clinical disease [25–27], however, the correlation of the
degree of VZV viraemia with clinical disease severity has not been
investigated in patients with acute primary VZV infection.
T cell responses are believed to be important in controlling the
virus and preventing viral reactivation. Virus specific proliferative
T cell responses were found to be impaired in immunosuppressed
individuals with severe disease [28,29] and proliferative T cell
responses in the first 72 hours since the onset of symptoms were
shown to be associated with milder disease [30]. Interestingly,
VZV specific antibody titres did not seem to correlate with clinical
disease severity [30,31]. These studies suggest that a strong VZV-
specific T cell response early in infection may protect individuals
from severe disease. However, this possibility and the associations
between the frequency and functional T cell responses with viral
load in acute primary VZV infection have not been investigated in
detail.
In order to further understand the host pathogen interactions
during primary VZV infection, we set out to investigate the degree
of viral load, and phenotype and functionality of T cell responses
in relation to clinical disease severity in a cohort of adult patients
with acute primary VZV infection.
Materials and Methods
Subjects
Fresh heparinized venous blood samples were obtained from 34
adult individuals with acute primary varicella infection who were
admitted sequentially to the Infectious Diseases Hospital in Sri
Lanka. Ethics was obtained from the Ethics Committee of
University of Sri Jayawardanapura, Sri Lanka and the Oxfordshire
Research Ethics Committee, UK. It is common practice in Sri
Lanka that even individuals with mild disease will attend hospital
and will frequently be hospitalised. Written consent was gained
from all donors. Mean age of the donors was 32.8 (SD61.7) years
and the mean duration of symptoms since the onset of rash at the
time of taking the first blood sample 4.5 days (SD61.7, median
4.5, range 3 to 7 days).
The clinical disease severity was assessed by using the severity
scale defined by Vazquez M et al. which classifies severity of
infection based on the number and character of the lesions,
presence or absence of fever, systemic signs and also the subjective
assessment of the patient [32]. Accordingly, 12 had mild infection,
and 22 had moderate to severe infection. 13 patients had more
.500 skin lesions and 7 had ,50 skin lesions. The remaining 14
patients had skin lesions in the range of 50 to 500.
Ex vivo ELISpot assays and intracellular cytokine assays
Peripheral blood mononuclear cells (PBMC) were obtained
from fresh heparinized blood by Ficoll-Hypaque density gradient
centrifugation. They were then resuspended in RPMI 1640 plus
10% fetal calf serum (FCS) for ex vivo ELISpot assays and ex vivo
ICS assays and in RPMI 1640 plus 10% human serum for cell
cultures.
Ex vivo Elispot assays were performed as previously described
[33]. Briefly, ELISpot plates (Millipore Corp., Bedford, Massa-
chusetts, USA) were coated with anti-human IFNc antibody
overnight (Mabtech AB, Nacka, Sweden). The plates were washed
six times with RPMI 1640 and incubated for 1 hour with RPMI-
1640 and 10% FCS. 0.1610
6 PBMC were added to a final volume
of 200 ml. The live attenuated varicella zoster vaccine (Varilrix:
GlaxoSmithKline) was added to a final concentration of 10*4 pfu/
ml. All peptides were tested in duplicate. PHA was included as a
positive control and an irrelevant peptide was included as a
negative control. Positive responses were defined as mean plus 3
standard deviations of the irrelevant peptide responses. The plates
were incubated overnight at 37uC and 5% CO2. The cells were
removed and the plates developed with a second biotinylated Ab
to human IFNc and washed a further six times. The plates were
developed with streptavidin-alkaline phosphatase (Mabtech AB)
and colorimetric substrate, and the spots enumerated using an
automated ELISpot reader. Background (cells plus media) was
subtracted and data expressed as number of spot-forming units
(SFU) per 10
6 PBMC.
To determine IFNc production, ex vivo- PBMC or T-cell lines
were stimulated at 1610
6 to 2610
6/ml in RPMI 1640 plus 10%
FCS with the VZV live attenuated vaccine for 16 hours according
to manufacturers instructions in the presence of Brefeldin A (BD
GolgiStop
TM). Cells were washed and stained with anti CD3
(FITC), anti CD4 (PerCP) (BD Biosciences) and anti CD8 (PE).
Cells were then permeabilized and fixed with Cytofix/Cytoperm
(BD Biosciences) and then stained for intracellular IFNc (APC).
Cells were acquired on a CyAn
TM (DakoCytomation) and
analysed using FlowJo software.
Tetramer and phenotypic staining and flow cytometry
DRB1*1501 iTAg MHCII tetramers were purchased from
Beckman Coulter. DRB1*1501 tetramer was complexed to VZV
gE peptide 54 (aa531–545; TSPLLRYAAWTGGLA) [42] or
VZV IE63 peptide 24 (aa229–243; QRAIERYAGAETAEY) [38].
These peptides were chosen on the basis that they were commonly
recognised in previous studies [38,42]. Unless stated otherwise, cell
lines and PBMC were incubated with 2 mg/ml HLA class II
tetramer for 60 min at 37uC in RPMI-1640 and 10% human
serum. We analyzed the tetramer expression within the CD4
+T
cell subset by gating on the lymphocytes and excluding B cells,
monocytes and dead cells (via probe positive population).
The cell surface marker Abs CD4-pacific blue (Biolegend),
CD14-PerCP, C19-PerCP and 7-aminoactinomycin D (7-AAD)
(all BD Pharmingen) were added for 20 minutes at room
temperature. For phenotypic analysis of tetramer-positive CD4
+
T cells, antibodies to CD38 (APC); CD62L (APC); CCR7 (Pe-
Cy7) and CLA (FITC) were added with the other surface
antibodies. Stained cells were washed with PBS, and fixed in
0.5% PBS/formaldehyde. Cells were acquired on a CyAn
TM
(DakoCytomation) and analysed using FlowJo software.
Quantitative real time PCR
Quantitative real time PCR was performed as previously
described using the ABI Prism 7700 sequence detector system
[34,35]. Forward primers (59-CGTACACGTATTTT-
CAGTCCTCTTC-39) and reverse primers (59-GGCTTA-
GACGTGGAGTTGACA-39) for VZV ORF29 and a probe (59-
(FAM)CCCGTGGAGCGCGTCGAAA(TAMRA)-39) were used
[35].
Standard curves for the viral gene were generated by using a
plasmid with serial 10 fold dilutions. The plasmid was generated
in-house by inserting viral DNA extracted from the VZV live
attenuated vaccine in to a pCR 2.1-TOPOH vector. Briefly, the
PCR fragment amplified from the ORF29 was cloned in to the
vector using one Shot DH5a
TM-T1 chemically competent E.coli
according to the manufacturers instructions (Invitrogen, United
Kingdom). Clones containing the vector and the insert were
isolated and plasmid DNA was extracted from the competent E.
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manufacturer’s instructions. Digestion of plasmid DNA was
performed to determine the molecular weight of the DNA
fragment which was inserted into the vector and subsequently
sequenced to ensure that the insert was of the correct sequence.
Detection of viral loads in patients with primary VZV
infection
Briefly, viral DNA was extracted from whole EDTA blood
samples from the patients using Gentra PureGene Kit (D5000). All
PCRs were performed in triplicate. The standard curves used for
data analysis all had a correlation coefficient exceeding 0.985.
PCR mixtures were amplified for 2 min at 50uC, 10 min at 95u,
60 cycles of 15 s at 95uC and 1 min at 60uC. Data was analyzed
using the PE Applied Biosystems- sequence detection systems 1.5.
The real-time fluorescence values were measured by the quantity
of a reporter dye FAM released during amplification. The
threshold cycle value (Ct) for each reaction reflects the cycle
number in which the fluorescence exceeds the threshold. The
threshold limit was set in the linear phase of exponential
amplification after viewing the log linear view of the amplification
plot. All samples were done in triplicate and expressed as median.
Results
Viral load and clinical disease severity in adult patients
with primary VZV infection
Tables 1 and 2 document the clinical characteristics of the cohort.
We confirmed a significant positive correlation with clinical disease
severity and the age of the patients in our cohort (Spearman’s
Table 1. Clinical characteristics of cohort.
Donor Age
Duration of symptoms prior to
blood sample Total severity score Complications
SLCP01 42 3 15 Bacterial meningitis
SLCP02 31 5 11
SLCP03 19 2 7
SLCP04 79 3 7
SLCP05 31 5 15
SLCP06 20 9 6 AML
SLCP07 19 4 6
SLCP08 40 5 11
SLCP09 43 2 10
SLCP10 13 4 7 Infected lesions
SLCP11 37 3 20 Nephrotic syn. (steroids)
SLCP12 21 2 10
SLCP14 31 5 11
SLCP14 54 7 11
SLCP15 58 5 6
SLCP16 31 6 9
SLCP17 50 14 9 VZV Cerebellitis
SLCO18 29 5 6
SLCP19 46 6 12
SLCP20 25 5 11
SLCP21 32 3 7
SLCP22 46 5 25 VZV associated Severe pneumonia
SLCP23 58 7 13
SLCP24 25 6 15 SLE (steroids)
SLCP25 19 4 7
SLCP26 27 3 6
SLCP27 29 3 12
SLCP28 17 5 9
SLCP29 28 4 6
SLCP30 19 4 10
SLCP31 24 8 12
SLCP32 24 3 8
SLCP33 17 3 3
SLCP34 32 4 9 Melanoma
doi:10.1371/journal.pone.0003789.t001
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viral loads were significantly higher in those aged over 25 years
(P=0.01) when compared to those between 18 to 25 years (Fig 1A).
In addition, a significant correlation was observed between the age of
the patients and the viral loads (P=0.02, Spearman’s r=0.39).
We next went on to determine the viral loads in relation to
varying clinical disease severity. Indeed the viral loads in patients
with moderate and severe disease (median 1,652 viral copies/ml
blood) were significantly higher (P,0.001) than in those with mild
disease (median 124 viral copies/ml blood) (Fig 1B). A significant
correlation (P=0.0005, Spearmans r=0.56) was also observed
between the clinical disease severity and the number of viral copies
in these patients.
Within the disease severity scale, a significant emphasis is given
to the number of skin lesions. We compared the viral loads in
patients with different numbers of skin lesions. The number of
viral copies was significantly higher in patients with .500 skin
lesions, when compared to those with ,500 skin lesions (P=0.008)
(Fig 1C). Thus, the presence of .500 skin lesions was an indicator
of the presence of a higher viral load in patients with acute
infection.
Figure 1. Relation of clinical characteristics to viral load. (A) Viral loads in patients with primary VZV who were 25 years or younger compared
to older individuals. (B) Quantity of viral copies in the peripheral blood of patients with varying severity of primary VZV infection. (C) Quantity of viral
copies in patients with primary VZV infection with different numbers of skin lesions. Line shows median.
doi:10.1371/journal.pone.0003789.g001
Table 2. Relation of age to number of lesions.
Age ,50 51–100 101–500 .500
16–25 4 4 2 1
26–40 1 3 2 7
.41 2 2 1 5
doi:10.1371/journal.pone.0003789.t002
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load were associated with an increase in age and also that a higher
viral load was associated with more severe clinical disease severity
and the presence of .500 skin lesions, we went on to determine
whether differences in T cell responses might associate with viral
load and disease severity.
T cell responses in patients with primary VZV infection
We initially proceeded to investigate the functional T cell
responses by using ex vivo IFNc ELISpot assays with peripheral
blood mononuclear cells (PBMC) derived from twelve individuals.
Although varied a frequency of ex vivo IFNc responses to the VZV
live vaccine were seen in these patients, 4 patients had no detectable
VZV-specific IFNc production despite the presence of symptoms for
3 to 5 days. VZV-specific IFNc responses were higher in patients
with mild infection (median 622 spot forming units/million cells)
than in patients with moderate/severe disease (median 40 spot
forming units/million cells). Patients with ,500 skin lesions had
significantly higher (median 615 spot forming units/million cells)
VZV-specific IFNc responses (P=0.02) than patients with .500
skin lesions (median 30 spot forming units/million cells).
As patients with more severe disease appeared to have lower
VZV-specific T cell responses, we then went on to determine if
there was any association between the viral loads in these patients
and VZV-specific IFNc responses. A significant negative correla-
tion was observed between the viral loads and VZV-specific ex vivo
IFNc responses in such individuals (Spearman’s r=20.85,
P,0.001) (Fig. 2).
We have previously mapped several VZV CD4+ T cell epitopes
in VZV glycoproteins gI and gE and immediate early proteins IE4
and IE63 [36–38]. We and others have found that in healthy VZV
immune donors the majority of the VZV-specific T cell responses
were from the CD4+ subset of T cells [36,37,39]. Using ex vivo
intra cellular cytokine assays we observed that even in acute
primary varicella infection, IFNc production was predominantly
from the CD4+ subset of T cells within the peripheral blood (Fig 3).
However, clearly it will be important to investigate other sites such
as the skin, to determine whether VZV-specific CD8+ T cells are
preferentially sequestered at particular sites.
Analysis of the frequency and phenotype of gE and IE63
DRB1*1501 tetramer specific responses in patients with
acute VZV infection
Following analysis of the functional responses of VZV-specific T
cells in patients with acute VZV infection using whole viral vaccine
Figure 2. Inverse correlation of viral loads with ex vivo IFNc
ELISpot responses of patients with acute varicella infection.
Spearman’s r=20.85, p,0.001.
doi:10.1371/journal.pone.0003789.g002
Figure 3. CD4+ T cells represent the main source of VZV-specific IFNc production during acute infection. Example of ex vivo intracellular
cytokine analysis of PBMC of a patient with acute varicella infection. The VZV vaccine was used as the antigenic stimulus. Cells are gated on CD3+.
doi:10.1371/journal.pone.0003789.g003
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and phenotype of common gE and IE63 DRB1*1501 epitope
specific CD4+ T cell responses in these patients. This approach
allows the detection of antigen specific T cells without the
requirement of a functional outcome. In our cohort, 8 patients
were of the appropriate DRB1*1501 HLA genotype. Frequencies
of gE DRB1*1501 tetramer specific T cells ranged from 0 to
0.097% (median 0.0157% of CD4+ T cells) while the frequencies
of IE63 DRB1*1501 tetramer specific T cells ranged from 0 to
0.092% (median 0.007% of CD4+ T cells). During acute infection
VZV-tetramer specific T cells and showed an activated phenotype
with preferential expression of skin homing receptors compared to
the total CD4+ population (Fig 4). Cutaneous lymphocyte
associated antigen (CLA) was expressed by significantly more of
the tetramer-positive cells compared to the total CD4+ population
(median 10% and 0.9% respectively; P,0.01). Furthermore CD38
was also expressed by significantly more of the tetramer-positive
cells than the total CD4+ population (70% and 28% respectively;
P,0.001). There was no significant difference in CCR7
expression, but the expression of CD62L was markedly higher in
the tetramer-positive population than in the total CD4+
population (26.7% and 12.4% respectively) but this did not reach
statistical significance. Clearly the total CD4+ T cell population
will contain T cells specific for other VZV epitopes and therefore
phenotypic comparisons should be interpreted with caution.
Nevertheless, the functional T cell responses elicited are not high
(maximum 770 spot forming units per million PBMC) and it is
therefore likely that the vast majority of the peripheral blood
CD4+ T cells are not specific for VZV.
Discussion
It is well established that adults are more likely to develop severe
disease and complications during primary VZV infection [1,3] and
our results confirm that the clinical disease severity score increases
significantly with advancing age. In this study, we have extended
these findings to show that there is a positive correlation between
age and peripheral blood viral load during disease.
Patients with .500 skin lesions had significantly higher viral
loads than patients with fewer lesions. Therefore, the presence of
.500 skin lesions appears to be a good clinical indicator of high
viral loads in peripheral blood. This was in contrast to
observations in herpes zoster (HZ), where rash severity does not
correlate with the extent of viraemia in acute HZ. Rather the viral
load in HZ appeared to be associated with age and immune status
of the individual [34].
A large variation was observed in VZV-specific IFNc responses
in patients with acute infection. Patients with milder disease had
higher VZV-specific IFNc responses than those with more severe
disease (p=0.05). Moreover, patients with a .500 skin lesions had
lower IFNc producing VZV-specific T cells than those with fewer
lesions. However, the virus specific IFNc responses were
significantly lower than those observed in many other acute viral
infections [40,41] despite evidence of detectable virus in the blood.
We observed a significant inverse correlation between rapid
IFNc production by VZV-specific T cells and viral load. Such an
inverse correlation suggests that IFNc-producing T cells may be
important for early control of viral replication. In order to examine
responses at the epitope-specific level, we also used HLA-peptide
tetrameric complexes to identify the presence of specific T cells.
The tetramer-positive T cell phenotype was that of intermediate
differentiation with evidence of recent activation. Furthermore
10% of the cells expressed CLA and thus would be likely to have
skin homing capacity. It will clearly be important to examine other
markers putatively associated with skin homing such as CCR4 and
CCR10. CCR7 expression was maintained in the majority of cells
suggesting that these cells retained the capacity for ongoing lymph
Figure 4. VZV-specific CD4+ T cells phenotypic analysis. Comparison of the expression of CLA (cutaneous lymphocyte associated antigen-1),
lymph node homing markers and activation markers on the tetramer-binding cells (circles) and total CD4+ population (triangles). Cells are gated on
CD4+ Via probe
2CD14
2CD19
2 cells.
doi:10.1371/journal.pone.0003789.g004
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associated with viraemia. The frequencies of gE and IE63 epitope-
specific T cells were higher in patients with acute infection
compared to previous studies in healthy immune donors where the
median levels were 0.003% and 0.006% respectively [38,42].
Frequencies of tetramer-binding CD4+ T cells were however in a
similar range to those observed during acute parvovirus B19 and
hepatitis C infections [43–45]. Nevertheless the inverse association
between functional VZV-specific T cell responses and both viral
load and disease severity argues in support of a potential role of
such levels of T cells in the control of viral replication. In addition,
although CD8+ T cells are thought to play a major role in
controlling acute herpes virus infection, virus specific CD4+ T cells
have also been shown to possibly play an important role. For
instance, it was observed that IFNc secreting CD4+ T cell
responses developed earlier in patients with asymptomatic CMV
infection than in patients with symptomatic infection and were
associated with clearance of the virus. Moreover, despite the
presence of specific antibody and CMV-specific CD8+ T cells,
clearance of virus in symptomatic patients only occurred after
emergence of IFNc secreting CD4+ T cells [46,47]. However, it is
also possible that as patients with more severe clinical disease had
a higher number of skin lesions, virus specific T cells could be
localized in the skin thereby reflecting a lower number of specific
T cells in the peripheral blood. We have observed that the
peripheral blood response to VZV is dominated by CD4+ T cells
during acute infection, which is analogous to observations in
healthy immune donors [36–39]. It is not clear whether such
relative paucity of viral-specific CD8+ T cells reflects impaired
class I antigen presentation or selective targeting of VZV-specific
CD8+ T cells by the virus. VZV inhibits the IFNc mediated
induction of class I [17,48], but many other viruses employ such
an immune evasion strategy (eg CMV, HIV) and yet CD8+ T cell
responses are readily detected to these viruses. Understanding such
mechanisms will clearly be important for identification of novel
therapeutic options relevant to VZV and other herpes viruses.
It will clearly be important to undertake similar analyses in
other populations in order to establish whether the findings are
consistent between, for example, tropical and temperate climates.
Whilst possible explanations for differences in epidemiology are
debated and may include viral, climate and host factors,
acquisition of primary disease during adulthood consistently
associates with more severe disease in diverse populations. It will
also be important to undertake longitudinal analyses, both in the
presence and absence of anti-viral therapy in order to characterise
the T cell correlates of disease and viral load over time.
In summary, these data provide a mechanistic link between
clinical disease severity and T cell responses during primary
infection with VZV. The presence of .500 skin lesions was a
useful and simple clinical indication of high viral loads and
impaired VZV-specific functional T cell responses. Individuals
with maintained IFNc effector function of VZV-specific T cells
had lower viral loads and lower disease severity scores.
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